Salas-Gutiérrez I, Reyes-Melo I, Chiquete E, Ruiz-Flores ML, Cantú-Brito C

Language: Spanish
References: 13
Page: 299-305
PDF size: 206.73 Kb.

ABSTRACT

Introduction: It is not clear what is the most effective treatment for the prevention of recurrent stroke or transient ischemic attack (TIA) in patients with patent foramen ovale and cryptogenic ischemic cerebrovascular disease (CVD).
Objectve: To determine the efficacy of the percutaneous closure of patent foramen ovale in the prevention of recurrent stroke in patients with cryptogenic stroke or TIA.
Methods: We performed a search in PubMed, EMBASE, KoreaMed, LILACS, and the Cochrane Librarydatabases. We included randomized controlled trials evaluating the efficacy of percutaneous closure of patent foramen ovale compared with standard medical therapy for the prevention of recurrent stroke in adults with cryptogenic CVD. Were recalculated relative risks [RR, and 95%confidence interval (CI)] for the primary outcome of fatal or non-fatal stroke, TIA or all-cause mortality. The combined analysis of the effect size was calculated based on the intention-to-treat population (ITT) for the primary outcome.
Results: Of 108 references initially identified, we included 3 studies that satisfactorily met the criteria for this analysis: CLOSUREI (n = 909), PC Trial (n = 980) and RESPECT (n = 414), published between 2012 and 2013. The meta-analysis of the 3 studies was on 2,303 patients in the intention-to-treat populations of each study (percutaneous closure n = 1,150; n = 1,153 medical treatment). The combined analysis recalculated showed no significant reduction of the risk for the primary endpoint of fatal or non-fatal stroke, TIA or all-cause mortality (RR: 0.72; 95% CI: 0.49-1.06). This effect was not different with the sequential exclusion of each study.
Conclusions: The best available evidence to date shows that percutaneous closure of patent foramen ovale is not superior to standard medical therapy in preventing recurrent stroke or death in patients with cryptogenic acute ischemic CVD.

REFERENCES

1. Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009; 40: 1195-203.

2. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, et al. Prevalence ofpotential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc 1999; 74: 862-9.

3. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 1172-9.

4. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009; 40: 2349-55.

5. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent orguilty? Evidence from a prospective population-based study. J Am CollCardiol 2006; 47: 440-5.

6. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patentforamen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transientischemic attack. Am Heart J 1995; 130: 1083-8.

7. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associatedwith patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740-6.

8. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyondequipoise. JAMA 2005; 294: 366-9.

9. Dalen JE. Are patients with a patent foramen ovale at increased risk of stroke?A billion dollar question. Am J Med 2007; 120: 472-4.

10. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenicstroke with patent foramen ovale. N Engl J Med 2012; 366: 991-9.

11. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083-91.

12. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092-100.

13. Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, Dinicolantonio JJ, Lansky AJ, et al. Stroke prevention by percutaneous closure of patent foramen ovale: asystematic review and meta-analysis. Heart 2013; 21. [Epub ahead of print].